Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATLCAR.CD138 |
Synonyms | |
Therapy Description |
ATLCAR.CD138 are autologous T-lymphocytes that are engineered to express a chimeric antigen receptor that targets CD138, potentially resulting in an immune response against CD138-expressing tumor cells and leading to an antitumor response (PMID: 31040928). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATLCAR.CD138 | CART-138|CD138.CAR | ATLCAR.CD138 are autologous T-lymphocytes that are engineered to express a chimeric antigen receptor that targets CD138, potentially resulting in an immune response against CD138-expressing tumor cells and leading to an antitumor response (PMID: 31040928). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|